Pulmonary administration of granulocyte colony stimulating factor
US5284656A · kind A · utility
237Cited by
3References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 29, 1992 |
| Grant date | Feb 8, 1994 |
| Priority date | — |
| Expiry date | Sep 29, 2012 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S530/838
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Granulocyte-colony stimulating factor (G-CSF) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration in accordance with this invention results in significant elevation of the neutrophil levels that compares favorably with delivery by subcutaneous injection. G-CSF can be administered in this manner to medically treat neutropenia, as well as to combat or prevent infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.